Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms?
about
Who, What, Where, When (and Maybe Even Why)? How the Experience of Sexual Reward Connects Sexual Desire, Preference, and PerformanceBremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trialVascular alterations and sexual function in systemic sclerosis.Advances in pharmacotherapy for treating female sexual dysfunction.Bladder, bowel, and sexual dysfunction in Parkinson's diseaseA double-blind placebo-controlled trial of maca root as treatment for antidepressant-induced sexual dysfunction in women.Effects of mindfulness training on body awareness to sexual stimuli: implications for female sexual dysfunction.Comparing the effects of treatment with sildenafil and cognitive-behavioral therapy on treatment of sexual dysfunction in women: a randomized controlled clinical trial.Diabetes and sexual dysfunction: current perspectives.Exploration of therapeutic targets for sexual dysfunctions: lessons learned from the failed stories.Mindfulness-Based Sex Therapy Improves Genital-Subjective Arousal Concordance in Women With Sexual Desire/Arousal Difficulties.Pharmacological Advances in the Management of Sexual Dysfunction.Expression and distribution of key enzymes of the cyclic GMP signaling in the human clitoris: relation to phosphodiesterase type 5 (PDE5).Effects of a Mindfulness Task on Women's Sexual Response.Why are there no FDA-approved treatments for female sexual dysfunction?Does Repeated Testing Impact Concordance Between Genital and Self-Reported Sexual Arousal in Women?Sildenafil in women with sexual arousal disorder following spinal cord injury.A practical guide to female sexual dysfunction: An evidence-based review for physicians in Canada.
P2860
Q22252670-F7EC39D5-833F-49FC-A98B-205968088BF7Q30276805-FB28C556-8104-4274-BEBB-03312050511BQ34218886-35F01748-119E-4506-A8CB-35E9982D9306Q34465301-0D056E0B-A8B4-494A-BE92-993C8A7D559FQ35209869-1E0E9A12-6970-4957-BF70-A17A0057C203Q35543695-1A66B8C0-9E52-4E69-AA3D-A9324323D846Q37012258-09929C1C-F861-4F3D-851E-7B76BBB24F53Q37058843-ADEF54A3-1E4A-46B0-8E7F-6926483778F3Q37630425-60B500CA-EB52-455C-B14D-BCB332C829FCQ37825899-7E13835D-9B1B-4B68-B69E-38DAAD715B56Q38902845-EB922CB4-0A30-4CB3-8229-0E0E9BF826A1Q42341588-E008CBBD-07DE-4211-9507-F95A034FCBBFQ42490401-DA1EB6BF-0487-4BD4-835D-302B448BAD7BQ47562382-BC224678-FF90-4E6D-A786-1C91355F8E36Q47566021-7D631461-AD08-42EE-91E1-578286A2ADF0Q47617992-0344B372-245B-4EBE-87A5-DEC62898559DQ51545883-4972643E-C76F-4FAE-A36F-E05C5D5E3402Q55297841-C5C53A14-39CC-495A-8774-5C32761EC7BE
P2860
Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms?
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Phosphodiesterase type 5 inhib ...... faulty protocols or paradigms?
@en
Phosphodiesterase type 5 inhib ...... faulty protocols or paradigms?
@nl
type
label
Phosphodiesterase type 5 inhib ...... faulty protocols or paradigms?
@en
Phosphodiesterase type 5 inhib ...... faulty protocols or paradigms?
@nl
prefLabel
Phosphodiesterase type 5 inhib ...... faulty protocols or paradigms?
@en
Phosphodiesterase type 5 inhib ...... faulty protocols or paradigms?
@nl
P1476
Phosphodiesterase type 5 inhib ...... faulty protocols or paradigms?
@en
P2093
Meredith L Chivers
Raymond C Rosen
P304
P356
10.1111/J.1743-6109.2009.01599.X
P433
P577
2009-11-19T00:00:00Z